# Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

> **NCT06161909** · PHASE3 · UNKNOWN · sponsor: **Fujian Medical University Union Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma Thoracic Stage II
- Esophageal Squamous Cell Carcinoma Thoracic Stage III
- Esophageal Squamous Cell Carcinoma Thoracic Stage IV

## Interventions

- **DRUG:** sintilimab

## Key facts

- **NCT ID:** NCT06161909
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-10
- **Primary completion:** 2025-12
- **Final completion:** 2026-02
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06161909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06161909, "Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06161909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*